Kaleido offers a comprehensive platform designed to simplify blockchain adoption for enterprises, focusing on various applications such as digital asset management, tokenization, and the development of custom blockchain networks. The platform supports a wide range of use cases, including Central Bank Digital Currencies (CBDCs), capital markets, supply chain management, and insurance, among others. Kaleido's infrastructure is built for scalability, privacy, and security, ensuring that organizations can efficiently launch and manage blockchain solutions tailored to their specific needs. With features like a digital asset platform, Web3 middleware, and chain infrastructure, Kaleido enables businesses to create and manage assets at scale while streamlining operations through a robust orchestration engine.

One of the standout technologies offered by Kaleido is its Zero Knowledge Token Transfer service, which allows for secure and private transactions on the Ethereum network using advanced cryptographic techniques. This service enables users to conduct anonymous token transfers, ensuring that transaction details remain confidential. By leveraging zero-knowledge proofs, Kaleido enhances privacy and security for various applications, including trading and governance token management. The platform's flexibility allows enterprises to deploy blockchain networks across public, private, and consortium chains, making it a versatile solution for organizations looking to innovate and transform their operations through blockchain technology.

Netherlands

Kaleido is an award-winning, enterprise-grade Web3 platform making blockchain and digital assets radically simple for organizations to adopt. 

Kaleido provides security, compliance, and scalability for the most stringent enterprise requirements within highly regulated industries. 

Kaleido’s platform is ISO27K and SOC 2 Type 2 certified with built-in high availability and disaster recovery, achieving 99.99% uptime over the past 5 years.

Cancer

Infectious Diseases

Metabolic Diseases

Kaleido

Urea cycle disorder

Kaleido’s Microbiome Metabolic Therapies, or MMTs, are designed to drive &nbsp;the function and distribution of the microbiome’s existing microbes in &nbsp;order to decrease or increase the production of metabolites, or to &nbsp;advantage or disadvantage certain bacteria in the microbiome community. &nbsp;The Company’s initial MMT candidates are targeted, synthetic glycans &nbsp;that are orally administered, have limited systemic exposure, and are &nbsp;selectively metabolized by enzymes in the microbiome.&nbsp;Kaleido utilizes &nbsp;its discovery and development platform to study MMTs in microbiome &nbsp;samples to rapidly advance MMT candidates rapidly into clinical studies &nbsp;in healthy subjects and patients. These human clinical studies are &nbsp;conducted under regulations supporting research with food, evaluating &nbsp;safety, tolerability and potential markers of effect. For MMT candidates &nbsp;that are further developed as therapeutics, the Company conducts &nbsp;clinical trials under an Investigational New Drug (IND) or regulatory &nbsp;equivalent outside the U.S., and in Phase 2 or later development.
<a href="https://investors.kaleido.com/news-releases/news-release-details/kaleido-biosciences-reports-second-quarter-2020-financial">Source</a>

KB195

Chronic obstructive pulmonary disease

Kaleido’s Microbiome Metabolic Therapies, or MMTs, are designed to drive &nbsp;the function and distribution of the microbiome’s existing microbes in &nbsp;order to decrease or increase the production of metabolites, or to &nbsp;advantage or disadvantage certain bacteria in the microbiome community. &nbsp;The Company’s initial MMT candidates are targeted, synthetic glycans &nbsp;that are orally administered, have limited systemic exposure, and are &nbsp;selectively metabolized by enzymes in the microbiome.
<a href="https://investors.kaleido.com/news-releases/news-release-details/kaleido-biosciences-reports-positive-results-non-ind-study">Source</a>

KB109

Inflammatory bowel disease

Kaleido’s Microbiome Metabolic Therapies, or MMTs, are designed to drive &nbsp;the function and distribution of the microbiome’s existing microbes in &nbsp;order to decrease or increase the production of metabolites, or to &nbsp;advantage or disadvantage certain bacteria in the microbiome community. &nbsp;The Company’s initial MMT candidates are targeted, synthetic glycans &nbsp;that are orally administered, have limited systemic exposure, and are &nbsp;selectively metabolized by enzymes in the microbiome.&nbsp;Kaleido utilizes &nbsp;its discovery and development platform to study MMTs in microbiome &nbsp;samples to rapidly advance MMT candidates rapidly into clinical studies &nbsp;in healthy subjects and patients. These human clinical studies are &nbsp;conducted under regulations supporting research with food, evaluating &nbsp;safety, tolerability and potential markers of effect. For MMT candidates &nbsp;that are further developed as therapeutics, the Company conducts &nbsp;clinical trials under an Investigational New Drug (IND) or regulatory &nbsp;equivalent outside the U.S., in Phase 2 or later development.
<a href="https://investors.kaleido.com/news-releases/news-release-details/kaleido-biosciences-announces-first-patient-dosed-clinical-study">Source</a>

Kaleido

Company Details